Zoetis Inc (ZTS)
175.20
+0.57
(+0.33%)
USD |
NYSE |
Nov 15, 15:21
Zoetis Research and Development Expense (Quarterly): 167.00M for Sept. 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 167.00M |
| June 30, 2024 | 171.00M |
| March 31, 2024 | 162.00M |
| December 31, 2023 | 174.00M |
| September 30, 2023 | 152.00M |
| June 30, 2023 | 146.00M |
| March 31, 2023 | 142.00M |
| December 31, 2022 | 148.00M |
| September 30, 2022 | 134.00M |
| June 30, 2022 | 135.00M |
| March 31, 2022 | 122.00M |
| December 31, 2021 | 138.00M |
| September 30, 2021 | 132.00M |
| June 30, 2021 | 120.00M |
| March 31, 2021 | 118.00M |
| December 31, 2020 | 133.00M |
| September 30, 2020 | 112.00M |
| June 30, 2020 | 111.00M |
| March 31, 2020 | 107.00M |
| December 31, 2019 | 132.00M |
| September 30, 2019 | 112.00M |
| June 30, 2019 | 111.00M |
| March 31, 2019 | 102.00M |
| December 31, 2018 | 125.00M |
| September 30, 2018 | 108.00M |
| Date | Value |
|---|---|
| June 30, 2018 | 102.00M |
| March 31, 2018 | 97.00M |
| December 31, 2017 | 110.00M |
| September 30, 2017 | 96.00M |
| June 30, 2017 | 86.00M |
| March 31, 2017 | 90.00M |
| December 31, 2016 | 108.00M |
| September 30, 2016 | 90.00M |
| June 30, 2016 | 88.00M |
| March 31, 2016 | 90.00M |
| December 31, 2015 | 109.00M |
| September 30, 2015 | 91.00M |
| June 30, 2015 | 84.00M |
| March 31, 2015 | 80.00M |
| December 31, 2014 | 124.00M |
| September 30, 2014 | 93.00M |
| June 30, 2014 | 92.00M |
| March 31, 2014 | 87.00M |
| December 31, 2013 | 121.00M |
| September 30, 2013 | 93.00M |
| June 30, 2013 | 95.00M |
| March 31, 2013 | 90.00M |
| December 31, 2012 | 121.00M |
| September 30, 2012 | 94.00M |
| June 30, 2012 | 92.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
107.00M
Minimum
Mar 2020
174.00M
Maximum
Dec 2023
137.80M
Average
134.50M
Median
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc | 2.598B |
| Regeneron Pharmaceuticals Inc | 1.272B |
| Vertex Pharmaceuticals Inc | 875.90M |
| Alnylam Pharmaceuticals Inc | 270.93M |
| Biomarin Pharmaceutical Inc | 184.90M |